Bascom Lecture Series on Current Issues in Clinical Medicine
The George S. Bascom Memorial Lecture/Workshop Series on Current Issues in Clinical Medicine, started in 1996 and named after a local physician, brings distinguished experts to K-State to present to faculty, students, medical care providers, and the general public about challenges faced in clinical medicine and research.
November 1, 2024
 |
Webster Cavenee, PhD Ludwig Institute for Cancer Research, San Diego University of California San Diego |
Scientific lecture at 3:30pm: Fiedler Hall Auditorium
Reception at 5-6pm: Johnson Cancer Research Center
Title: Tumor Heterogeneity: An Active Process That Dictates Therapeutic Response
About Dr. Cavenee:
Dr. Cavenee did his graduate and postdoctoral training in cell biology, biochemistry and human genetics. He received his B.S. from Kansas State University and his Ph.D. with honors in 1977 from the University of Kansas School of Medicine. He then did postdoctoral work at the Jackson Laboratory, the Massachusetts Institute of Technology and the Howard Hughes Medical Institute at the University of Utah. He has held faculty positions at the University of Cincinnati and McGill University (where he was the Founding Director of the Ludwig Institute for Cancer Research, Montreal Branch). From 1991-2015 he was Founding Director of the Ludwig Institute for Cancer Research, San Diego Branch and Distinguished Professor of Medicine at the University of California at San Diego. Between 2015-2020, he was Director, Strategic Alliances-CNS of Ludwig Cancer Research with global responsibilities. He is now Director Emeritus of the Ludwig Institute for Cancer Research and Distinguished Professor Emeritus at the University of California at San Diego.
Dr. Cavenee’s most recognized accomplishments are in the genetic basis of cancer predisposition, tumor progression, oncogenic cellular signaling and the use of genetic approaches for cancer diagnosis and prognosis. His efforts led to an international alliance against brain cancer and he now serves on the Board of Directors of the resultant Global Coalition for Adaptive Research, a 501(c)3 organization that is the engine for the GBM AGILE global clinical trial as well as adaptive trials in other diseases. He also has served on many NIH review and advisory panels including the Boards of Scientific Counselors of the National Cancer Institute and the National Institute of Environmental Health Sciences and advisory boards for several NIH Cancer Center Support, SPORE and PO1 grants, as well those of several private foundations and international institutions. He has been President of the American Association for Cancer Research. He has also served on the Boards of Directors or Scientific Advisory Boards of a dozen biotechnology companies in four countries and has founded three others.
Dr. Cavenee is an elected member/fellow of the US National Academy of Sciences, the US National Academy of Medicine, the German Academy of Science Leopoldina, the Chinese Academy of Engineering, the EU Academy of Science, the AACR Academy, the International Union Against Cancer, the American Society for Clinical Investigation and the American Academy of Microbiology. He has published ~400 scientific papers and received more than 125 honors, most notably the Charles S. Mott Prize of the General Motors Cancer Research Foundation, the Albert Szent-Gyorgyi Award from the National Foundation for Cancer Research, the Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research from the American Association for Cancer Research, the Feldman Founder’s Award from the National Brain Tumor Society, the Lifetime Achievement Award from the Society for Neuro-Oncology, the Helen Keller Award from the Association for Research in Vision and Ophthalmology, the Friendship Award from the People’s Republic of China and Fellowship in the German Helmholtz Association.